Lead Product(s) : Lenzilumab
Therapeutic Area : Pharmacology/Toxicology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The patent covers the use of lenzilumab to prevent or treat cytokine release syndrome (CRS), neurotoxicity and otherwise inhibit or reduce incidence or severity of CAR-T-related toxicities in patients undergoing CAR-T cell therapy.
Brand Name : Humaneered
Molecule Type : Large molecule
Upfront Cash : Not Applicable
December 28, 2020
Lead Product(s) : Lenzilumab
Therapeutic Area : Pharmacology/Toxicology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?